{"id":660,"date":"2025-11-14T00:34:43","date_gmt":"2025-11-14T08:34:43","guid":{"rendered":"https:\/\/getasecondopinion.ai\/blog\/?p=660"},"modified":"2025-11-14T00:34:43","modified_gmt":"2025-11-14T08:34:43","slug":"fda-approves-ziftomenib-for-acute-myeloid-leukemia","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/","title":{"rendered":"FDA Approves Ziftomenib for Acute Myeloid Leukemia"},"content":{"rendered":"\n

The treatment landscape for acute myeloid leukemia (AML) has recently seen a significant development with the U.S. Food and Drug Administration (FDA) granting full approval<\/strong> to ziftomenib<\/strong> (Komzifti\u2122) for adult patients diagnosed with relapsed or refractory (R\/R) AML who harbor a susceptible NPM1<\/em> (Nucleophosmin 1) mutation and have no satisfactory alternative treatment options. This landmark decision, announced on November 13, 2025, introduces a novel, once-daily, targeted oral therapy to a patient population historically characterized by poor outcomes and limited effective options at relapse1,2<\/sup>.<\/p>\n\n\n\n

\n\n\n\n

The Critical Role of the <\/strong>NPM1<\/em><\/strong> Mutation in AML<\/strong><\/h2>\n\n\n\n

Acute myeloid leukemia is a heterogeneous hematologic malignancy. The presence of specific genetic alterations is critical for disease classification, prognosis, and therapeutic targeting. The NPM1<\/em><\/strong> gene, which is involved in ribosome biogenesis and genomic stability, is the most frequently mutated gene<\/strong> in adult AML, affecting approximately 30%<\/strong> of cases3<\/sup>.<\/p>\n\n\n\n

Wild-type NPM1 protein is predominantly localized in the nucleolus. However, mutations in NPM1<\/em><\/strong> (most commonly Type A, B, and D) lead to a loss of the nucleolar localization signal and the creation of a new nuclear export signal. This results in the aberrant cytoplasmic mislocalization<\/strong> of the mutant NPM1 protein4<\/sup>. This cytoplasmic accumulation disrupts normal cellular functions and is a major oncogenic driver, promoting leukemogenesis through altered gene expression, including the upregulation of key transcription factors like HOXA<\/em> and MEIS1<\/em>5<\/sup>.<\/p>\n\n\n\n

While NPM1<\/em><\/strong>-mutated AML is often associated with a favorable prognosis in the frontline setting, patients who relapse or are refractory to initial therapy face markedly diminished survival rates, often with less than a 10% complete response rate to subsequent chemotherapy6,7<\/sup>.<\/p>\n\n\n\n

\n\n\n\n

Ziftomenib: A Potent and Selective Menin Inhibitor<\/strong><\/h2>\n\n\n\n

Ziftomenib is a small-molecule, potent, and highly selective menin inhibitor<\/strong>8<\/sup>. Its mechanism of action directly addresses the core oncogenic driver of NPM1<\/em><\/strong>-mutated AML.<\/p>\n\n\n\n

Mechanism of Action<\/strong><\/h3>\n\n\n\n

The protein menin<\/strong> (encoded by the MEN1<\/em> gene) forms a crucial complex with the Lysine [K]-specific Methyltransferase 2A (KMT2A, formerly MLL) protein. This Menin-KMT2A complex<\/strong> is aberrantly recruited to the promoters of leukemogenic genes, such as HOXA<\/em> and MEIS1<\/em>, when NPM1<\/em><\/strong> is mutated and cytoplasmic5<\/sup>.<\/p>\n\n\n\n

Ziftomenib works by specifically disrupting the interaction<\/strong> between menin and KMT2A. By preventing the formation of this complex, ziftomenib effectively downregulates the expression of the HOX\/MEIS1<\/em> transcriptional program. This downstream inhibition leads to the terminal differentiation and apoptosis of the leukemic blasts, thereby exerting its anti-leukemic activity8,9<\/sup>.<\/p>\n\n\n\n

\n
\n
\n

Better Treatment, Lower Cost – No Catch.<\/h3>\n\n\n\n

Find safer, more effective medications with fewer side effects – often for less money. It\u2019s fast, free, and personalized. Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

Pivotal Efficacy and Safety Data: The KOMET-001 Trial<\/strong><\/h2>\n\n\n\n

The FDA approval of ziftomenib is primarily supported by the data from the pivotal Phase 2 portion of the global, multicenter, open-label, single-arm KOMET-001 trial<\/strong> (NCT04067336)1,10<\/sup>. The trial evaluated ziftomenib monotherapy at a recommended phase 2 dose (RP2D) of 600 mg once daily in a heavily pretreated cohort of adults with R\/R NPM1<\/em><\/strong>-mutated AML1<\/sup>.<\/p>\n\n\n\n

Key Efficacy Outcomes<\/strong><\/h3>\n\n\n\n

The primary efficacy endpoint was the rate of Complete Remission (CR)<\/strong> plus CR with Partial Hematologic Recovery (CRh)<\/strong>. Secondary endpoints included the duration of CR+CRh, the rate of conversion from transfusion dependence to independence, and minimal residual disease (MRD) negativity1,10<\/sup>.<\/p>\n\n\n\n

The efficacy population included 112 adult patients with R\/R NPM1<\/em><\/strong>-mutated AML, with a median follow-up of 4.2 months (range, 0.1 to 41.2 months)1<\/sup>.<\/p>\n\n\n\n

Response Metric<\/strong><\/td>Value (95% Confidence Interval)<\/strong><\/td>Median Duration<\/strong><\/td><\/tr>
CR + CRh Rate<\/strong><\/td>21.4%<\/strong> (14.2, 30.2)1<\/sup><\/td>5.0 months<\/strong> (1.9, 8.11<\/sup><\/td><\/tr>
Complete Remission (CR) Rate<\/td>17.0% (10.5, 25.2)1<\/sup><\/td>–<\/td><\/tr>
CR with Partial Hematologic Recovery (CRh) Rate<\/td>4.5% (1.5, 10.1)1<\/sup><\/td>–<\/td><\/tr>
Transfusion Independence Rate<\/td>21.2%1<\/sup> (Among 66 patients dependent at baseline)<\/td>–<\/td><\/tr>
MRD Negativity Rate (Among CR\/CRh responders tested)<\/td>65%2<\/sup><\/td>–<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Source: FDA Approval and KOMET-001 Trial Data (Adapted)<\/em>1,2<\/sup><\/em><\/p>\n\n\n\n

Notably, the trial data indicated that clinically meaningful response rates were comparable regardless of previous therapy, including prior treatment with venetoclax or prior hematopoietic stem cell transplantation (HSCT)2<\/sup><\/em>. For responders (patients achieving a complete or composite complete response), the median overall survival was 16.4 months (95% CI: 9.6, 20.4), compared to 3.5 months (95% CI: 2.5, 4.0) for non-responders2<\/sup>.<\/p>\n\n\n\n

Safety Profile<\/strong><\/h3>\n\n\n\n

The safety profile observed in the KOMET-001 trial showed that ziftomenib was generally well-tolerated. Common Grade treatment-emergent adverse events (TEAEs) included cytopenias, such as febrile neutropenia<\/strong>, anemia<\/strong>, and thrombocytopenia<\/strong>1,10<\/sup>.<\/p>\n\n\n\n

A class effect for menin inhibitors is differentiation syndrome<\/strong>; in the KOMET-001 trial, differentiation syndrome occurred in 13% of the overall safety population (15% Grade3<\/sup>) and was reported as manageable with protocol-defined mitigation strategies1<\/sup>. Importantly, the prescribing information for ziftomenib does not include a Boxed Warning for QTc interval prolongation, which can be a key advantage for patients on multiple concurrent medications2<\/sup>.<\/p>\n\n\n\n

\n
\n
\n

Experiencing Side Effects?
Let\u2019s Rethink Your Meds.<\/h3>\n\n\n\n

Explore treatment options that may work better for your body – with fewer side effects and lower costs. It\u2019s fast, free, and tailored to you. Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

Implications for R\/R <\/strong>NPM1<\/em><\/strong>-Mutated AML<\/strong><\/h2>\n\n\n\n

The FDA approval of ziftomenib marks a significant advance in precision medicine for AML. For adult patients with R\/R NPM1<\/em><\/strong>-mutated AML, for whom treatment options have been severely limited, this targeted oral menin inhibitor provides a new, non-intensive therapeutic pathway.<\/p>\n\n\n\n

The favorable safety profile, including manageable differentiation syndrome and the lack of a Boxed Warning for QTc prolongation, underscores its potential to improve outcomes for a vulnerable patient population, particularly those who are older or unable to tolerate intensive chemotherapy or transplant2<\/sup>. The achievement of durable, MRD-negative responses across various prior treatment exposure subgroups highlights ziftomenib’s potential to establish a new standard of care in this molecularly defined, high-unmet-need setting.<\/p>\n\n\n\n

As clinical development continues, combination studies evaluating ziftomenib with intensive and non-intensive chemotherapy regimens are ongoing, with the potential to integrate menin inhibition into earlier lines of therapy for a broader range of patients with NPM1<\/em><\/strong>-mutated and KMT2A<\/em>-rearranged AML11<\/sup>.<\/p>\n\n\n\n

\n
\n
\n

Stop Overpaying for Meds.<\/h3>\n\n\n\n

Coupons aren\u2019t your only option – see if safer, more effective, and lower-cost alternatives are available. It\u2019s fast, personalized, and 100% free. Learn More \u2192<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

\n\n\n\n

References (11)<\/strong><\/h2>\n\n\n\n
    \n
  1. FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukemia with an <\/strong>NPM1<\/em><\/strong> Mutation.<\/strong> U.S. Food and Drug Administration. November 13, 2025.\u00a0 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation<\/a><\/li>\n\n\n\n
  2. Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI\u2122 (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory <\/strong>NPM1<\/em><\/strong>-Mutated Acute Myeloid Leukemia.<\/strong> Kura Oncology, Inc. News Release. November 13, 2025.\u00a0 https:\/\/www.globenewswire.com\/news-release\/2025\/11\/13\/3187609\/0\/en\/Kura-Oncology-and-Kyowa-Kirin-Announce-FDA-Approval-of-KOMZIFTI-ziftomenib-the-First-and-Only-Once-Daily-Targeted-Therapy-for-Adults-with-Relapsed-or-Refractory-NPM1-Mutated-Acute-.html<\/a><\/li>\n\n\n\n
  3. Falini B, Brunetti L, Sportoletti P, Martelli MP.<\/strong> NPM1<\/em>-mutated acute myeloid leukemia: from bench to bedside. Blood<\/em>. 2020;136(15):1707-1721.\u00a0 https:\/\/ashpublications.org\/blood\/article\/136\/15\/1707\/459468\/NPM1-mutated-acute-myeloid-leukemia-from-bench-to<\/a><\/li>\n\n\n\n
  4. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.<\/strong> NIH. PMC<\/em>.\u00a0 https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10543165\/<\/a><\/li>\n\n\n\n
  5. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and <\/strong>NPM1<\/em><\/strong>-Mutated Acute Myeloid Leukemia.<\/strong> PubMed Central<\/em>.\u00a0 https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11036224\/<\/a><\/li>\n\n\n\n
  6. Ziftomenib in Relapsed or Refractory <\/strong>NPM1<\/em><\/strong>-Mutated AML.<\/strong> Journal of Clinical Oncology<\/em>. 2025;43(31):3381-3390.\u00a0 https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01694<\/a><\/li>\n\n\n\n
  7. Issa G, Bidikian A, Venugopal S, et al.<\/strong> Clinical outcomes associated with NPM1<\/em> mutations in patients with relapsed or refractory AML. Blood Adv<\/em>. 2023 Mar 28;7(6):933-942.\u00a0 https:\/\/ashpublications.org\/bloodadvances\/article\/7\/6\/933\/492576\/Clinical-outcomes-associated-with-NPM1-mutations-in<\/a><\/li>\n\n\n\n
  8. Komzifti (ziftomenib) dosing, indications, interactions, adverse effects, and more.<\/strong> Medscape Reference<\/em>.\u00a0 https:\/\/reference.medscape.com\/drug\/ziftomenib-4000546<\/a><\/li>\n\n\n\n
  9. Ziftomenib in relapsed\/refractory (R\/R) <\/strong>NPM1<\/em><\/strong>-mutant acute myeloid leukemia (AML): Phase 1b\/2 clinical activity and safety results from the pivotal KOMET-001 study.<\/strong> ASCO Publications<\/em>.\u00a0 https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.6506<\/a><\/li>\n\n\n\n
  10. First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia.<\/strong> ClinicalTrials.gov<\/em>. Identifier: NCT04067336.\u00a0 https:\/\/clinicaltrials.gov\/study\/NCT04067336<\/a><\/li>\n\n\n\n
  11. Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed <\/strong>NPM1<\/em><\/strong>-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007.<\/strong> Blood<\/em>. 2024;144(Supplement 1):214.\u00a0 https:\/\/ashpublications.org\/blood\/article\/144\/Supplement%201\/214\/530335\/Ziftomenib-Combined-with-Intensive-Induction-7-3<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    The treatment landscape for acute myeloid leukemia (AML) has recently seen a significant development with the U.S. Food and Drug Administration (FDA) granting full approval to ziftomenib (Komzifti\u2122) for adult patients diagnosed with relapsed or refractory (R\/R) AML who harbor a susceptible NPM1 (Nucleophosmin 1) mutation and have no satisfactory alternative treatment options. This landmark […]<\/p>\n","protected":false},"author":3,"featured_media":662,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[366,368,371,370,374,373,369,372,329,367],"class_list":["post-660","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-drugs","tag-acute-myeloid-leukemia","tag-aml","tag-fda-approval","tag-hematology","tag-komet-001-trial","tag-menin-inhibitor","tag-npm1-mutation","tag-relapsed-refractory-aml","tag-targeted-therapy","tag-ziftomenib"],"yoast_head":"\nFDA Approves Ziftomenib for Acute Myeloid Leukemia - Get a Second Opinion<\/title>\n<meta name=\"description\" content=\"FDA approves Ziftomenib for Acute Myeloid Leukemia, offering a new targeted treatment option for AML cancer patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Ziftomenib for Acute Myeloid Leukemia - Get a Second Opinion\" \/>\n<meta property=\"og:description\" content=\"FDA approves Ziftomenib for Acute Myeloid Leukemia, offering a new targeted treatment option for AML cancer patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Get a Second Opinion\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/getasecondopinion\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T08:34:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"G2O\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G2O\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"21 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/\"},\"author\":{\"name\":\"G2O\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\"},\"headline\":\"FDA Approves Ziftomenib for Acute Myeloid Leukemia\",\"datePublished\":\"2025-11-14T08:34:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/\"},\"wordCount\":1196,\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg\",\"keywords\":[\"Acute Myeloid Leukemia\",\"AML\",\"FDA Approval\",\"Hematology\",\"KOMET-001 Trial\",\"Menin Inhibitor\",\"NPM1 Mutation\",\"Relapsed Refractory AML\",\"targeted therapy\",\"Ziftomenib\"],\"articleSection\":[\"New Drugs\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/\",\"name\":\"FDA Approves Ziftomenib for Acute Myeloid Leukemia - Get a Second Opinion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg\",\"datePublished\":\"2025-11-14T08:34:43+00:00\",\"description\":\"FDA approves Ziftomenib for Acute Myeloid Leukemia, offering a new targeted treatment option for AML cancer patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg\",\"contentUrl\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"A professional 2D header illustration showing the announcement \u201cFDA Approves Ziftomenib for Acute Myeloid Leukemia\u201d in large white type on a semi\u2011transparent blue backer; below are stylized red-orange leukemia blood cells, an amber prescription bottle, a blue blister pack of pills, and a clipboard with a checkmark, all on a cool blue background.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/medications\\\/new-drugs\\\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Insights\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medications\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/medications\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"New Drugs\",\"item\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/category\\\/medications\\\/new-drugs\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"FDA Approves Ziftomenib for Acute Myeloid Leukemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"name\":\"Get a Second Opinion\",\"description\":\"Insights\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#organization\",\"name\":\"Get a Second Opinion\",\"url\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"contentUrl\":\"https:\\\/\\\/getasecondopinion.ai\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/G2O-logo-full.png\",\"width\":1000,\"height\":129,\"caption\":\"Get a Second Opinion\"},\"image\":{\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/getasecondopinion\",\"https:\\\/\\\/www.instagram.com\\\/getasecondopinion\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.getasecondopinion.ai\\\/blog\\\/#\\\/schema\\\/person\\\/9fbb863e981c8982fb301d0644843b20\",\"name\":\"G2O\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g\",\"caption\":\"G2O\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Ziftomenib for Acute Myeloid Leukemia - Get a Second Opinion","description":"FDA approves Ziftomenib for Acute Myeloid Leukemia, offering a new targeted treatment option for AML cancer patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Ziftomenib for Acute Myeloid Leukemia - Get a Second Opinion","og_description":"FDA approves Ziftomenib for Acute Myeloid Leukemia, offering a new targeted treatment option for AML cancer patients.","og_url":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/","og_site_name":"Get a Second Opinion","article_publisher":"https:\/\/www.facebook.com\/getasecondopinion","article_published_time":"2025-11-14T08:34:43+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg","type":"image\/jpeg"}],"author":"G2O","twitter_card":"summary_large_image","twitter_misc":{"Written by":"G2O","Est. reading time":"21 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/#article","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/"},"author":{"name":"G2O","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20"},"headline":"FDA Approves Ziftomenib for Acute Myeloid Leukemia","datePublished":"2025-11-14T08:34:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/"},"wordCount":1196,"publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg","keywords":["Acute Myeloid Leukemia","AML","FDA Approval","Hematology","KOMET-001 Trial","Menin Inhibitor","NPM1 Mutation","Relapsed Refractory AML","targeted therapy","Ziftomenib"],"articleSection":["New Drugs"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/","url":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/","name":"FDA Approves Ziftomenib for Acute Myeloid Leukemia - Get a Second Opinion","isPartOf":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/#primaryimage"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg","datePublished":"2025-11-14T08:34:43+00:00","description":"FDA approves Ziftomenib for Acute Myeloid Leukemia, offering a new targeted treatment option for AML cancer patients.","breadcrumb":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/#primaryimage","url":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg","contentUrl":"https:\/\/www.getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/11\/FDA-Approves-Ziftomenib-for-Acute-Myeloid-Leukemia.jpg","width":1536,"height":1024,"caption":"A professional 2D header illustration showing the announcement \u201cFDA Approves Ziftomenib for Acute Myeloid Leukemia\u201d in large white type on a semi\u2011transparent blue backer; below are stylized red-orange leukemia blood cells, an amber prescription bottle, a blue blister pack of pills, and a clipboard with a checkmark, all on a cool blue background."},{"@type":"BreadcrumbList","@id":"https:\/\/www.getasecondopinion.ai\/blog\/medications\/new-drugs\/fda-approves-ziftomenib-for-acute-myeloid-leukemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Insights","item":"https:\/\/www.getasecondopinion.ai\/blog\/"},{"@type":"ListItem","position":2,"name":"Medications","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/medications\/"},{"@type":"ListItem","position":3,"name":"New Drugs","item":"https:\/\/www.getasecondopinion.ai\/blog\/category\/medications\/new-drugs\/"},{"@type":"ListItem","position":4,"name":"FDA Approves Ziftomenib for Acute Myeloid Leukemia"}]},{"@type":"WebSite","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#website","url":"https:\/\/www.getasecondopinion.ai\/blog\/","name":"Get a Second Opinion","description":"Insights","publisher":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.getasecondopinion.ai\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#organization","name":"Get a Second Opinion","url":"https:\/\/www.getasecondopinion.ai\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","contentUrl":"https:\/\/getasecondopinion.ai\/blog\/wp-content\/uploads\/2025\/09\/G2O-logo-full.png","width":1000,"height":129,"caption":"Get a Second Opinion"},"image":{"@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/getasecondopinion","https:\/\/www.instagram.com\/getasecondopinion"]},{"@type":"Person","@id":"https:\/\/www.getasecondopinion.ai\/blog\/#\/schema\/person\/9fbb863e981c8982fb301d0644843b20","name":"G2O","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/21b03bf2b185bfb0dd4d13c2214225de3355abca7b52e424ee73d37b573644a0?s=96&d=mm&r=g","caption":"G2O"}}]}},"_links":{"self":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/comments?post=660"}],"version-history":[{"count":2,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/660\/revisions"}],"predecessor-version":[{"id":663,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/posts\/660\/revisions\/663"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media\/662"}],"wp:attachment":[{"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/media?parent=660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/categories?post=660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.getasecondopinion.ai\/blog\/wp-json\/wp\/v2\/tags?post=660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}